Advancing gene therapy development with a multi-serotype AAV affinity resin

Biochemist by education, Nicolas Laroudie worked at Généthon, France between 2001 and 2011 as Head of Downstream Development. He led a team developing and scaling-up purification processes for AAV, retroviral and lentiviral vectors used for gene therapy treatments. He then joined Merck Millipore as a BioManufacturing Engineer and supported European customers for all DSP technologies with a strong focus on chromatography. In particular, he took an active role in the establishment of a fully continuous, large-scale disposable DSP process for the purification of a monoclonal antibody, within the framework of a large multi-company European consortium. Next he joined Thermo Fisher Scientific in 2019 as Field Application Specialist for purification, supporting the technical implementation of POROS and CaptureSelect chromatography products in south-western Europe.

Quentin Bazot is a molecular virologist. He received his PhD from the Ecole Normale Supérieure (ENS) de Lyon in 2012. After a postdoctoral training at the Imperial College London, he joined the CGT Catapult where he led viral vector process and manufacturing development activities. In 2020 Quentin joined ABL where he is currently leading AAV process development and innovation programs working towards the optimization of AAV production and purification.